Under pathological conditions such as in Alzheimer’s disease and Down syndrome, altered amyloidogenic pathway and increased APP dose promote Aβ accumulation, Aβ aggregation, as well as the formation of insoluble fibrils into amyloid plaques. Here, APP is linked to amyloidosis.